NCT07198971 Feasibility Study Incorporating Music Therapy to Optimise the Smoking Cessation Process Coordinated by a Tobacco Addiction Nurse in Smoking Patients Being Treated for Cancer
| NCT ID | NCT07198971 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle |
| Condition | Cancer (With or Without Metastasis) |
| Study Type | INTERVENTIONAL |
| Enrollment | 26 participants |
| Start Date | 2026-02-18 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 26 participants in total. It began in 2026-02-18 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The innovative nature of this project lies in the combination of three types of intervention: tobacco addiction treatment, music therapy and therapeutic education. Three disciplines that work together. 1. Tobacco addiction treatment: reducing consumption, quitting, 2. Music therapy: acting on emotions and reward circuits, 3. Therapeutic education: promoting independent healthy practices. Patients learn to use the soundtrack independently to help them manage withdrawal symptoms caused by reducing or stopping tobacco consumption. In this programme, patients play an active role on several levels: * working with the music therapist to create a personalised 'soundtrack'; * identifying situations in which music can help them manage withdrawal symptoms; * using music independently in their everyday lives. The music therapy protocol will be proposed in this study, the soundtrack is co-created by the music therapist and the patient based on the patient's musical tastes and needs. The fact that the patient can use the musical tool independently also gives them significant leverage in their withdrawal process, allowing them to act on withdrawal symptoms and the main factors contributing to relapse.
Eligibility Criteria
Inclusion Criteria: 1. Patients over the age of 18 2. Patients with tobacco-related or non-tobacco-related cancer (excluding blood cancer) 3. Patients who smoke daily 4. Patients wishing to begin a smoking cessation programme 5. Patients with a prognosis of \> 1 year 6. Patients who have given their informed, written and express consent 7. Patients affiliated with a French social security scheme Exclusion Criteria: 1. Patients with uncorrected hearing loss 2. Patients with unstable psychiatric conditions 3. Patients for whom regular follow-up is impossible for psychological, family, social or geographical reasons 4. Patients under guardianship, curatorship or judicial protection
Contact & Investigator
GONZALEZ Marie Laure, Tobacco Nurse
PRINCIPAL INVESTIGATOR
marie-laure.gonzalez@icm.unicancer.fr
Frequently Asked Questions
Who can join the NCT07198971 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer (With or Without Metastasis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07198971 currently recruiting?
Yes, NCT07198971 is actively recruiting participants. Contact the research team at aude.menteaux@icm.unicancer.fr for enrollment information.
Where is the NCT07198971 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT07198971 clinical trial?
NCT07198971 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. The principal investigator is GONZALEZ Marie Laure, Tobacco Nurse at marie-laure.gonzalez@icm.unicancer.fr. The trial plans to enroll 26 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.